Skip to search formSkip to main contentSkip to account menu

3,4-dihydroxybenzohydroxamic acid

Known as: Benzamide, N,3,4-trihydroxy-, Didox, N,3,4-trihydroxybenzamide 
A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsHydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Acute neuroinflammation induces AIS structural plasticity in a NOX2-dependent manner
BackgroundChronic microglia-mediated inflammation and oxidative stress are well-characterized underlying factors in… 
2013
2013
AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves… 
2004
2004
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase
Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of… 
Highly Cited
2003
Highly Cited
2003
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
2003
2003
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
PurposeTemozolomide (TMZ), an oral alkylating agent with good penetration of the blood-brain barrier, has shown efficacy in the… 
1999
1999
In Vivo and In Vitro Comparison of the Short‐Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti‐HIV‐1 Activity
Inhibitors of the cellular enzyme ribonucleotide reductase (hydroxyurea, [HU]) have been proposed as a new therapeutic strategy… 
1994
1994
Transgenic mouse model of pharmacologic induction of fetal hemoglobin: Studies using a new ribonucleotide reductase inhibitor, didox
Evaluation of pharmacologic agents that stimulate fetal hemoglobin production has been done mainly in baboons and macaques. We… 
1991
1991
Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by… 
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the… 
Highly Cited
1980
Highly Cited
1980
Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)